Breaking News Instant updates and real-time market news.

MLNT

Melinta Therapeutics

$5.65

-0.33 (-5.52%)

, YETI

Yeti

$27.65

0.015 (0.05%)

08:45
06/27/19
06/27
08:45
06/27/19
08:45

Largest borrow rate increases among liquid names

Latest data shows the largest indicative borrow rate increases among liquid option names include: Melinta Therapeutics (MLNT) 561.57% +23.02, YETI Holdings (YETI) 5.28% +1.34, Anthem (ANTM) 0.38% +0.13, Aphria (APHA) 74.94% +0.11, Enterprise Products (EPD) 0.81% +0.11, Devon Energy (DVN) 0.35% +0.08, Advanced Micro (AMD) 0.34% +0.06, PepsiCo (PEP) 0.31% +0.06, Salesforce (CRM) 0.29% +0.04, and Southern Co (SO) 0.29% +0.03.

MLNT

Melinta Therapeutics

$5.65

-0.33 (-5.52%)

YETI

Yeti

$27.65

0.015 (0.05%)

ANTM

Anthem

$278.86

-6.31 (-2.21%)

APHA

Aphria

$6.97

0.04 (0.58%)

EPD

Enterprise Products

$28.93

0.25 (0.87%)

DVN

Devon Energy

$28.73

0.81 (2.90%)

AMD

AMD

$29.92

1.08 (3.74%)

PEP

PepsiCo

$132.38

-1.42 (-1.06%)

CRM

Salesforce

$148.98

-0.38 (-0.25%)

SO

Southern Company

$54.98

-1.01 (-1.80%)

  • 09

    Jul

  • 09

    Jul

  • 09

    Jul

  • 10

    Jul

  • 15

    Jul

  • 07

    Aug

MLNT Melinta Therapeutics
$5.65

-0.33 (-5.52%)

06/20/19
GABE
06/20/19
NO CHANGE
GABE
Gabelli fears Melinta Therapeutics may declare bankruptcy
Gabelli analyst Kevin Kedra kept a Sell rating on Melinta Therapeutics. He recommended investors sell the name after Wednesday's news that the FDA had accepted the sNDA filing for Baxdela, which caused Melinta shares to rise over 220%, which Kedra called a "baffling stock move." He sees near-term cash concerns for the company, which ended Q1 with $117M in cash and $223M of debt, along with operating cash burn of about $20M in the quarter, and fears the company could be forced to declare bankruptcy.
06/20/19
HCWC
06/20/19
NO CHANGE
Target $13
HCWC
Buy
Melinta rally reflects 'deeply oversold situation,' says H.C. Wainwright
H.C. Wainwright analyst Ed Arce believes yesterday's 224% rally in shares of Melinta Therapeutics reflects a "deeply oversold situation, more than anything else." With that said, the analyst views the FDA's acceptance of Melinta's supplemental New Drug Application of Baxdela as "clearly positive news and an important milestone." To reflect the impact of the company's ongoing cost restructuring, Arce lowered his price target for the shares to $13 from $45. He affirms a Buy rating on Melinta Therapeutics.
06/20/19
WBBS
06/20/19
DOWNGRADE
Target $8
WBBS
Hold
Melinta Therapeutics downgraded to Hold from Speculative Buy at WBB Securities
WBB Securities downgraded Melinta Therapeutics to Hold from Speculative Buy with an $8 price target after the stock rose 224% yesterday to $6.41.
06/19/19
JEFF
06/19/19
NO CHANGE
Target $5
JEFF
Hold
Melinta rally on drug application acceptance overdone, says Jefferies
Jefferies analyst David Hoang views today's rally in shares of Melinta Therapeutics as overdone. The analyst keeps a Hold rating on the shares with a $5 price target. The stock is up 194% to $5.82 in midday trading the FDA accepted the company's supplemental new drug application for Baxdela for the community-acquired bacterial pneumonia. Baxdela approval and launch in this indication by 2020 should have been largely baked-in, Hoang tells investors in a research note.
YETI Yeti
$27.65

0.015 (0.05%)

05/17/19
JEFF
05/17/19
NO CHANGE
Target $45
JEFF
Buy
Yeti search trends show progress in both markets, says Jefferies
Jefferies analyst Randal Konik says his analysis of search trends and web data illustrates the premium positioning of Yeti relative to peers and that the company is making progress in both heritage and non-heritage markets. Traffic to YETI.com far outpaces that of competitors for both new and existing customers, Konik tells investors in a research note. The analyst continues to see "ample runway" for Yeti to expand its total addressable market. He keeps a Buy rating on the shares with a $45 price target.
05/03/19
05/03/19
DOWNGRADE

Fly Intel: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Yeti (YETI) downgraded to Neutral from Buy at Goldman Sachs with analyst Alexandra Walvis saying the company's "strong" sales and brand momentum are now better understood by investors. 2. Electronic Arts (EA) downgraded to Neutral at MKM Partners on valuation with analyst Eric Handler saying the risk-reward on the stock appears to be "less compelling." 3. Cognizant (CTSH) downgraded to Market Perform from Outperform at William Blair, to Underweight from Neutral at JPMorgan, to Neutral from Buy at Goldman Sachs, to Perform from Outperform at Oppenheimer, to Sector Weight from Overweight at KeyBanc, to Neutral from Outperform at Wedbush and to Hold from Strong Buy at Needham after the company's earnings and guidance missed consensus estimates. 4. Target (TGT) downgraded to Market Perform from Outperform at Bernstein with analyst Brandon Fletcher saying he thinks Target's continued emphasis on growth over cost containment is a "less wise" stance at this point. 5. Achillion (ACHN) downgraded to Underweight from Equal Weight at Barclays with analyst Geoffrey Meacham seeing a lack of near- to mid-term catalysts that are capable of changing the story on the stock. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
05/03/19
GSCO
05/03/19
DOWNGRADE
Target $33
GSCO
Neutral
Yeti downgraded to Neutral from Buy at Goldman Sachs
Goldman Sachs analyst Alexandra Walvis downgraded Yeti Holdings to Neutral from Buy while raising her price target for the shares to $33 from $31. The company's "strong" sales and brand momentum are now better understood by investors, Walvis tells investors in a research note following its Q1 results. The analyst sees a more balanced risk/return profile at current valuation levels.
06/17/19
BARD
06/17/19
NO CHANGE
Target $38
BARD
Outperform
Yeti tariff concerns likely overblown, says Baird
Baird analyst Peter Benedict believes the tariff concerns for Yeti are likely overblown. He said his work suggests P&L impacts would likely prove manageable. The analyst said the company has multiple levers available to re-base costs/adjust pricing if necessary. Benedict reiterated his Outperform rating and $38 price target on Yeti shares.
ANTM Anthem
$278.86

-6.31 (-2.21%)

06/25/19
SBSH
06/25/19
NO CHANGE
SBSH
Molina, Centene have most at stake from Texas Medicaid awards, says Citi
Citi analyst Ralph Giacobbe noted that Texas' "highly anticipated" STAR+PLUS contract for the states' higher acuity Medicaid members is expected to be awarded this Friday, June 28. Among the incumbents in the state, Molina (MOH) and Centene (CNC) have the most at stake, as their respective STAR+PLUS earnings contribute about 7% and 2%, respectively, of his and consensus estimates, Giacobbe tells investors. He estimates that the other incumbents - Anthem (ANTM), Cigna (CI) and UnitedHealth (UNH) - have 1% or less of their earnings at stake, adding that investor expectations are for the incumbents to largely retain business.
06/20/19
JEFF
06/20/19
NO CHANGE
JEFF
Amazon's PillPack looking to bypass PBMs, says Jefferies
Jefferies analyst Brian Tanquilut says his review of documents related to a case filed by CVS Health (CVS), which seeks to prevent a former CVS executive from joining PillPack, shows that Amazon.com (AMZN) is seeking to develop a service offering that would bypass pharmacy benefit managers and contract directly with payors. While it is difficult to predict the success of PillPack's efforts to bypass existing prescription payment structures, the court disclosure is a potential negative for PBMs like CVS Health, UnitedHealth (UNH), Anthem (ANTM) and Cigna (CI), Tanquilut tells investors in a research note.
05/16/19
COWN
05/16/19
NO CHANGE
COWN
Move lower in managed care stocks appears overdone, says Cowen
Cowen analyst Charles Rhyee lowered his target multiple for the managed care group slightly from recent historical levels, but said he believes the recent weakness in the space on concerns around "Medicare for All," the rebate rule and the Texas ACA decision appears overdone. The discount for managed care stocks relative to the broader market has risen to a multi-year high, but he argues that underlying market fundamentals are stronger than in the pre-ACA era and Rhyee contends that there is "still plenty of growth left" in the managed care space, particularly in government-sponsored business. Stocks in the group include Anthem (ANTM), Cigna (CI), Centene (CNC), Humana (HUM), Molina Healthcare (MOH), UnitedHealth (UNH) and WellCare (WCG).
05/10/19
05/10/19
UPGRADE

Fly Intel: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. 3D Systems (DDD) upgraded to Neutral from Underweight at JPMorgan with analyst Paul Coster noting the stock is down 25% this week after posting "lackluster" Q1 results. 2. Jones Lang LaSalle (JLL) upgraded to Buy from Neutral at Goldman Sachs with analyst Andrew Rosivach saying the company's earnings declined in Q1 due to tough comps, but this should reverse quickly. 3. Ford (F) upgraded to Buy from Neutral at BofA/Merrill with analyst John Murphy stating the company's earnings are starting to hit a "sustainable inflection" due to favorable product cadence in the North America market and its restructuring efforts. 4. Whirlpool (WHR) upgraded to Buy from Neutral at Longbow with analyst David MacGregor seeing earnings upside from better than expected North American margin performance, a "gradually improving" environment in the EMEA and a favorable cyclical turn in Latin America. 5. Anthem (ANTM), Centene (CNC), and UnitedHealth (UNH) upgraded to Buy from Neutral at Citi with analyst Ralph Giacobbe the magnitude of the selloff in managed care stocks on fears of Medicare for All has been "extreme and overdone". This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
APHA Aphria
$6.97

0.04 (0.58%)

05/24/19
JEFF
05/24/19
INITIATION
JEFF
Buy
Jefferies starts Aphria at Buy, says valuation 'not reflective of reality'
Jefferies analyst Owen Bennett initiated coverage of Aphria (APHA) with a Buy rating and C$15 price target. The stock closed yesterday down 33c to $6.41. The analyst says the company scores highly on his "strategic scorecard," or third overall behind only Canopy Growth (CGC) and Aurora Cannabis (ACB). Despite a "strong global outlook," Aphria's valuation is the cheapest across the space, with allegations around inflated assets/insider deals weighing on the shares, Bennett tells investors in a research note. The analyst expects a "significant re-rating" in the shares with "these issues now seemingly cleared up." He points out that the company's questionable relationships have been severed and a special committee review found assets had not been falsely inflated. Bennett believes Aphria continues to execute and that its valuation is "not reflective of reality."
06/10/19
PIPR
06/10/19
NO CHANGE
PIPR
Cannabis regulation could become top 2020 election issue, says Piper Jaffray
After Washington D.C. lobbyist Michael Esposito, who also works closely with President Trump's administration, spoke at his firm's conference, Piper Jaffray analyst Michael Lavery believes cannabis regulation could become a top 2020 election issue. By supporting cannabis, Trump may be able to incrementally broaden his appeal with swing voters without alienating his base, Esposito tells investors in a research note. Though Trump has indicated his willingness to support the STATES Act, his enthusiasm could depend on whether or not Elizabeth Warren, author of the bill, is his opponent, adds the analyst in a note titled "Handicapping US Legalization Outlook: Politics Are Complicated." And while Senate Majority Leader Mitch McConnell is a roadblock for legislation in the Senate, Trump could use executive orders between now and the election to show support for the industry, potentially relating to cannabis banking or medical research, says Lavery. The analyst has Overweight ratings on both Canopy Growth (CGC) and Tilray (TLRY). Other names in the space include Aphria (APHA), Aurora Cannabis (ACB), CV Sciences (CVSI), CannTrust Holdings (CNTTF), Cronos Group (CRON), General Cannabis (CANN), India Globalization Capital (IGC), MediPharm Labs (MLCPF) and Zynerba (ZYNE).
04/16/19
VERF
04/16/19
NO CHANGE
Target $8
VERF
Sell
Use Aphria results as guide and short Tilray shares, says Vertical Group
Vertical Group analyst Gordon Johnson tells investors to use Aphria's (APHA) fiscal Q3 results as a guide and build a short position in Tilray (TLRY). The analyst last week initiated coverage of Tilray with a Sell rating and $8 year-end price target. Despite expectations for growth in Canadian sales due to the growth expectations for the recreational cannabis market, Aphria's kilograms sold fell 22.7% quarter-over-quarter in the quarter reported yesterday, Johnson tells investors in an email to clients. The analyst maintains his negative bias on Tilray following Aphia's results. Shares of Tilray are up 54c to $49.78 in early trading.
05/24/19
05/24/19
INITIATION

Fly Intel: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Zoom Video (ZM) initiated with a Perform at Oppenheimer. 2. CannTrust (CTST) initiated with a Buy at BofA/Merrill. 3. Inseego (INSG) initiated with an Outperform at Cowen. 4. Falcon Minerals (FLMN) initiated with an Outperform at Baird. 5. Aphria (APHA) initiated with a Buy at Jefferies. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
EPD Enterprise Products
$28.93

0.25 (0.87%)

05/30/19
JRCO
05/30/19
INITIATION
Target $35
JRCO
Buy
Enterprise Products initiated with a Buy at Johnson Rice
Johnson Rice analyst Georg Venturatos initiated Enterprise Products with a Buy and $35 price target.
04/12/19
MUFG
04/12/19
NO CHANGE
Target $35
MUFG
Overweight
Enterprise Products cash flow more stable than for overall midstream, says MUFG
MUFG analyst Barrett Blaschke kept his Overweight rating and $35 price target on Enterprise Products after its Analyst Day. The analyst says that while the presentation was "relatively unrevealing", it offered insight on the management's view of "everything from crude oil to the petrochemical world." Blaschke remains positive on the stock, stating the company has a "market leading set of assets and a market price that does not currently reflect it."
04/02/19
04/02/19
UPGRADE
Target $32

Buy
Enterprise Products upgraded to Buy from Neutral at Goldman Sachs
As previously reported, Goldman Sachs analyst Michael Lapides upgraded Enterprise Products to Buy and raised his price target to $32 from $30 after the stock has underperformed relative to the large caps in recent months. The analyst also cites the company's improving cash flow, exposure to key themes that include a "leading position in crude oil and NGL exports", and its position as "one of the more integrated infrastructure portfolios within the sector", extending its footprint "further downstream than most midstream companies."
04/03/19
04/03/19
UPGRADE

Fly Intel: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Urban Outfitters (URBN) upgraded to Buy from Neutral at DA Davidson with analyst John Morris saying the data showcase the company's "green shoots in improving pricing architecture at the Anthropologie division with stronger pricing and lower markdown cadence at the Urban division." 2. Intelsat (I) upgraded to Overweight from Neutral at JPMorgan with analyst Philip Cusick saying the stock has declined 28% year-to-date and 38% since February 27 when a "slew of headlines all but halted" the C-Band Alliance's momentum in D.C. 3. e.l.f. Beauty (ELF) upgraded to Buy from Hold at Jefferies with analyst Stephanie Wissink saying he believes the company's improved merchandising focus will drive a "meaningful reversal" in sales trends. 4. Enterprise Products (EPD) upgraded to Buy from Neutral at Goldman Sachs with analyst Michael Lapides citing the company's improving cash flow, exposure to key themes that include a "leading position in crude oil and NGL exports," and its position as "one of the more integrated infrastructure portfolios within the sector," extending its footprint "further downstream than most midstream companies." 5. CommScope (COMM) upgraded to Strong Buy from Outperform at Raymond James with analyst Simon Leopold saying he believes the earnings accretion from the pending Arris (ARRS) acquisition is underappreciated and will provide at least 40% accretion versus management's forecast for over 30% and analyst estimates of 25%-43%. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
DVN Devon Energy
$28.73

0.81 (2.90%)

03/01/19
RBCM
03/01/19
DOWNGRADE
RBCM
Sector Perform
Devon Energy downgraded to Sector Perform from Outperform at RBC Capital
03/01/19
03/01/19
DOWNGRADE

Fly Intel: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. L Brands (LB) downgraded to Market Perform from Outperform at Bernstein with analyst Jamie Merriman saying her Outperform rating was based on a view that investors were paying for Bath & Body Works with a free option on Victoria's Secret. 2. American Airlines (AAL) and Delta Air Lines (DAL) downgraded to Hold from Buy at Deutsche Bank. 3. Devon Energy (DVN) downgraded to Sector Perform from Outperform at RBC Capital. 4. O'Reilly Automotive (ORLY) downgraded to Neutral from Overweight at Atlantic Equities with analyst Sam Hudson citing valuation and raised his price target to $400 from $370. 5. Maxar Technologies (MAXR) downgraded to Hold from Speculative Buy at TD Securities and to Underperformer from Neutral at CIBC. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
05/20/19
WELS
05/20/19
INITIATION
Target $40
WELS
Outperform
Devon Energy resumed with an Outperform at Wells Fargo
Wells Fargo resumed coverage of Devon Energy with an Outperform rating and $40 price target. With the assets in place to generate "significant" cash returns along with management's commitment to cash returns, shares of Devon offer valuation upside, Wells says in a research note.
05/31/19
MUFG
05/31/19
NO CHANGE
MUFG
MUFG lowers estimates for Devon Energy after sale of Canadian assets
MUFG analyst Michael McAllister maintained a Neutral rating and $38 price target on Devon Energy, and stripped out Canada from the company's estimates after Q2, due to Devon's sale of its Canadian assets to Canadian Natural Resources for $2.8B. The firm's 2019 and 2020 EPS estimates fall to $1.82 and $3.17, from $2.02 and $3.23, respectively. On the positive side, McAllister wrote in a research note titled 'One Step Closer to New Devon,' "completing the transaction before year-end should accelerate the debt repayment presented earlier this year."
AMD AMD
$29.92

1.08 (3.74%)

06/21/19
WELS
06/21/19
NO CHANGE
WELS
Wells Fargo weighs in on AMD joint-venture blacklist
Wells Fargo analyst Aaron Rakers noted that AMD is trading lower following the announcement that the U.S. Commerce Department has added Chinese affiliate Higon, who is a partner in the THATIC joint-venture with AMD, to a blacklist, preventing them from purchasing components from U.S. suppliers. Rakers kept an Outperform rating and $28 price target on AMD, stating that while there has not been a response from AMD, the company previously noted that it would not expect any material license revenue through the remainder of 2019, and AMD CEO Lisa Su previously confirmed that the company isn't licensing further chip designs to its China-backed joint venture. Rakers also noted that IP-related license revenue from THATIC totaled $88M, $52M, and $86M in 2016, 2017, and 2018, respectively.
06/13/19
OPCO
06/13/19
NO CHANGE
OPCO
Perform
Epyc2 positioning AMD for accelerated server share gains, says Oppenheimer
After meeting with management, Oppenheimer analyst Rick Schafer notes that AMD is poised to launch its new 7nm CPU line-up for server and PC, as well as new 7nm Vega. The analyst also points out that its Epyc2, based on Zen 2 architecture and launching in Q3, "takes a notable leap forward," expanding AMD's opportunities in HPC, Cloud and virtualization workloads. Schafer sees Epyc2 positioning AMD for accelerated server share gains and forecasts 7% or better share by end of year and 10% share by mid-2020. The analyst has a Perform rating on the stock.
06/26/19
WEDB
06/26/19
INITIATION
Target $35
WEDB
Outperform
AMD initiated with an Outperform at Wedbush
Wedbush analyst Matthew Bryson initiated AMD with an Outperform rating and $35 price target.
06/27/19
06/27/19
INITIATION
Target $35

Outperform
Wedbush bullish on AMD, initiates with an Outperform
As previously reported, Wedbush analyst Matthew Bryson initiated AMD (AMD) with an Outperform rating and $35 price target. The analyst views AMD's reemergence in CPUs as one of the likely major shifts in both the PC and data center markets over the next few years. Specifically, Bryson believes AMD's early adoption of a distributed "chiplet" architecture combined with a shift to leading edge geometries positions the company to take meaningful share from Intel (INTC) in both the PC and server markets over the next few years. Moreover, he expects AMD will also realize some more modest benefits on the GPU side, with its GPU business also poised to benefit from a resumption of more normalized channel sales, sales into Google (GOOG) Stadia, console transitions, and a recently signed agreement with Samsung (SSNLF) to share and license IP.
PEP PepsiCo
$132.38

-1.42 (-1.06%)

04/18/19
ARGS
04/18/19
NO CHANGE
Target $146
ARGS
Buy
PepsiCo price target raised to $146 from $128 at Argus
Argus analyst John Staszak raised his price target on PepsiCo to $146 and kept his Buy rating after its "strong Q1 results" in spite of the marketing costs and FX headwinds, saying the company continues to generate solid growth amid a weak consumer spending backdrop. The analyst also maintains his long-term earnings growth rate forecast of 8% for PepsiCo and believes that the company can attain its goal of $1B in annual cost savings and productivity gains.
05/14/19
WELS
05/14/19
NO CHANGE
Target $127
WELS
Market Perform
PepsiCo price target raised to $127 from $120 at Wells Fargo
Wells Fargo analyst Bonnie Herzog raised her price target for PepsiCo to $127 from $120 as she is incrementally more positive on the stock. The analyst reiterates a Market Perform rating on the shares.
04/18/19
RHCO
04/18/19
NO CHANGE
Target $120
RHCO
Hold
PepsiCo price target raised to $120 from $110 at SunTrust
SunTrust analyst William Chappell raised his price target on PepsiCo to $120 after its Q1 earnings beat with better than expected organic revenue growth of 5.2%. The analyst is keeping his Hold rating on the shares while lowering his Q2 EBITDA forecast to $3.44B from $3.61B to reflect the management's plans to "spend back the upside" of Q1 in the current quarter through higher marketing and advertising. Chappell also reiterates his concerns with PepsiCo's "ability to grow profits high-single-digits" in the coming years when it slows its advertising and marketing expenditure.
04/18/19
04/18/19
UPGRADE

Fly Intel: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. PepsiCo (PEP) upgraded to Neutral from Sell at Goldman Sachs with analyst Judy Hong citing its "strong" Q1 results that saw organic revenue accelerate to 5% and gross margins top expectations. 2. J.M. Smucker (SJM) upgraded to Equal Weight from Underweight at Morgan Stanley with analyst Pamela Kaufman saying she believes the company's reinvestment strategy will drive improved topline momentum across its key segments and should allow the company to return to positive organic growth in FY20. 3. Venator Materials (VNTR) upgraded to Outperform from Sector Perform at RBC Capital with analyst Arun Viswanathan saying he believes that the titanium dioxide "cycle is turning", with destocking activity nearing completion amid improving global demand and pricing. 4. Ecolab (ECL) upgraded to Buy from Neutral at Nomura Instinet with analyst Dan Dolev saying with the problematic energy business soon to be spun-off, Ecolab's "recession resistant qualities should stand out, warranting a significant premium to peers." 5. Qualcomm (QCOM) upgraded to Buy from Hold at DZ Bank. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
CRM Salesforce
$148.98

-0.38 (-0.25%)

06/21/19
WEDB
06/21/19
DOWNGRADE
Target $176
WEDB
Neutral
Tableau downgraded to Neutral, while price target raised to $176 at Wedbush
Wedbush analyst Steve Koening downgraded Tableau (DATA) to Neutral from Outperform to reflect the pending takeover by Salesforce (CRM). At the same time, the analyst raised his price target to $176 from $153, saying he expects Salesforce to handle the integration "carefully," and that the combination will likely see significant revenue synergy in 12-24 months, as Salesforce is able to leverage its visibility to major digital transformation initiatives to accelerate Tableau's business.
06/12/19
SBSH
06/12/19
DOWNGRADE
SBSH
Neutral
Citi sees competitive bidding process for Tableau as unlikely
Citi analyst Tyler Radke downgraded Tableau Software (DATA) to Neutral from Buy with a $178 price target to reflect the pending takeover by Salesforce (CRM). The analyst continues to see a competitive bidding process as unlikely. Radke continues to favor Alteryx (AYX) as his top pick given the company's combination of "strong top-line growth paired with near best-in-class unit economics and profitability." Further, he believes Alteryx's market opportunity may be underestimated. Talend (TLND) moves to the analyst's second pick.
06/13/19
RBCM
06/13/19
NO CHANGE
Target $181
RBCM
Outperform
Salesforce price target lowered to $181 from $183 at RBC Capital
RBC Capital analyst Matthew Hedberg lowered his price target on Salesforce (CRM) to $181 after its all-stock acquisition of Tableau (DATA). The analyst notes that the $15.7B price tag and "overlap with an existing analytics footprint" gives him some "pause" in endorsing the deal, but he is prepared to give Salesforce management the benefit of the doubt given the company's strong M&A track record. The analyst lowers his FY20 and FY21 EPS view by 20c and 26c to $2.69 and $3.27 respectively to reflect the deal's dilution, but keeps his Outperform rating on Salesforce shares.
06/19/19
UBSW
06/19/19
DOWNGRADE
Target $166
UBSW
Neutral
Tableau downgraded to Neutral from Buy at UBS
UBS analyst Jennifer Swanson Lowe downgraded Tableau Software (DATA) to Neutral from Buy while raising her price target for the shares to $166 from $159 to reflect the takeover by Salesforce (CRM).
SO Southern Company
$54.98

-1.01 (-1.80%)

06/04/19
KEYB
06/04/19
INITIATION
KEYB
Sector Weight
Southern Company initiated with a Sector Weight at KeyBanc
KeyBanc analyst Sophie Karp started Southern Company with a Sector Weight, saying that while the stock is trading at a "sizable discount" relative to its peer group average, the company faces "regulatory turnover and sizable rate cases" in three of its jurisdictions. Karp believes that Southern Company shares offer "limited potential for multiple expansion" in the near term.
02/22/19
EVER
02/22/19
UPGRADE
EVER
In Line
Southern Company upgraded to In Line from Underperform at Evercore ISI
06/13/19
MZHO
06/13/19
NO CHANGE
Target $55
MZHO
Neutral
Southern Company price target raised to $55 from $48.50 at Mizuho
Mizuho analyst Paul Fremont raised his price target for Southern Company to $55 from $48.50 while keeping a Neutral rating on the shares. The staff of the Georgia Public Service Commission is expected to provide positive feedback when it comments on the Southern re-baseline of the Vogtle project in July, Fremont tells investors in a research note. He believes the staff filing will acknowledge progress made by Southern on increasing the earned man hours and in reducing delays in the company's turnover performance.
02/22/19
02/22/19
UPGRADE
Target $52

In Line
Southern Company upgraded to In Line on valuation at Evercore ISI
As previously reported, Evercore upgraded Southern Company to In Line from Underperform and raised its price target to $52 from $45. Analyst Greg Gordon cites fair valuation for the rating change.

TODAY'S FREE FLY STORIES

BKNG

Booking Holdings

$1,871.84

4.82 (0.26%)

11:23
07/18/19
07/18
11:23
07/18/19
11:23
Periodicals
Breaking Periodicals news story on Booking Holdings »

Hedgeye adds Booking…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LQD

iShares iBoxx $ Investment Grade Corporate Bond

$123.46

-0.2 (-0.16%)

11:20
07/18/19
07/18
11:20
07/18/19
11:20
Options
Put buyer in Investment Grade Corporate Bond ETF »

Put buyer in Investment…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FULC

Fulcrum Therapeutics

$0.00

(0.00%)

11:18
07/18/19
07/18
11:18
07/18/19
11:18
Syndicate
Breaking Syndicate news story on Fulcrum Therapeutics »

Fulcrum Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jul

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

11:17
07/18/19
07/18
11:17
07/18/19
11:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

11:16
07/18/19
07/18
11:16
07/18/19
11:16
Technical Analysis
NYSE market internals summary »

Volume is below average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

11:15
07/18/19
07/18
11:15
07/18/19
11:15
General news
Treasury announced a $113 B 3-pronged package of shorter coupons »

Treasury announced a $113…

11:15
07/18/19
07/18
11:15
07/18/19
11:15
General news
Breaking General news story  »

8-Week Bill Auction to be…

11:15
07/18/19
07/18
11:15
07/18/19
11:15
General news
Breaking General news story  »

4-Week Bill Auction to be…

XOP

SPDR Oil Exploration and Production Fund

$24.46

-0.15 (-0.61%)

11:10
07/18/19
07/18
11:10
07/18/19
11:10
Options
Size put rolldown in Oil and Gas Exploration ETF »

Size put rolldown in Oil…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

11:10
07/18/19
07/18
11:10
07/18/19
11:10
General news
5-Yr Note Announcement CUSIP Number data reported »

5-Yr Note Announcement…

11:10
07/18/19
07/18
11:10
07/18/19
11:10
General news
5-Yr Note Announcement Offering Amount data reported »

5-Yr Note Announcement…

11:10
07/18/19
07/18
11:10
07/18/19
11:10
General news
7-Yr Note Announcement CUSIP Number data reported »

7-Yr Note Announcement…

11:10
07/18/19
07/18
11:10
07/18/19
11:10
General news
2-Yr Note Announcement CUSIP Number data reported »

2-Yr Note Announcement…

11:10
07/18/19
07/18
11:10
07/18/19
11:10
General news
7-Yr Note Announcement Offering Amount data reported »

7-Yr Note Announcement…

11:10
07/18/19
07/18
11:10
07/18/19
11:10
General news
6-Month Bill Announcement Offering Amount data reported »

6-Month Bill Announcement…

11:10
07/18/19
07/18
11:10
07/18/19
11:10
General news
2-Yr Note Announcement Offering Amount data reported »

2-Yr Note Announcement…

11:10
07/18/19
07/18
11:10
07/18/19
11:10
General news
2-Yr FRN Note Announcement CUSIP Number data reported »

2-Yr FRN Note…

11:10
07/18/19
07/18
11:10
07/18/19
11:10
General news
FX Action: USD-CAD »

FX Action: USD-CAD is on…

11:10
07/18/19
07/18
11:10
07/18/19
11:10
General news
2-Yr FRN Note Announcement Offering Amount data reported »

2-Yr FRN Note…

11:09
07/18/19
07/18
11:09
07/18/19
11:09
General news
3-Month Bill Announcement Offering Amount data reported »

3-Month Bill Announcement…

YGTY

SSLJ.com

$1.36

0.1 (7.94%)

11:06
07/18/19
07/18
11:06
07/18/19
11:06
Hot Stocks
SSLJ.com announces resignation of auditor »

SSLJ.com Limited…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SBPH

Spring Bank Pharmaceuticals

$5.23

0.12 (2.35%)

11:05
07/18/19
07/18
11:05
07/18/19
11:05
Hot Stocks
Spring Bank reports agreement for HBV antisense oligonucleotide compounds »

Spring Bank…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SSRM

SSR Mining

$15.23

0.335 (2.25%)

11:05
07/18/19
07/18
11:05
07/18/19
11:05
Options
SSR Mining call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Aug

AMRB

American River

$12.92

(0.00%)

11:03
07/18/19
07/18
11:03
07/18/19
11:03
Hot Stocks
American River increases quarterly dividend to 7c per share from 5c »

American River Bankshares…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jul

FULC

Fulcrum Therapeutics

$0.00

(0.00%)

11:02
07/18/19
07/18
11:02
07/18/19
11:02
Syndicate
Breaking Syndicate news story on Fulcrum Therapeutics »

Fulcrum Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jul

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.